Skip to main content
. 2017 Jun 13;38(8):1354–1370. doi: 10.1177/0271678X17713105

Figure 4.

Figure 4.

DMF treatment improved the peak latency of CAP, but not axonal refractoriness following severe chronic hypoperfusion. (a, b) DMF-treated hypoperfused mice had a reduced peak latency compared to vehicle-treated mice (*p < 0.05) indicating that DMF is able to improve conduction velocity of myelinated fibres. (c, d) Axonal refractoriness was not significantly altered by DMF treatment (p = 0.07). Data are presented as mean ± S.E.M. Student’s t test, *p < 0.05 n = 12 per group.